Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 7

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 7
---
  
    $125.42  
     7.3  
    $4,258 
  
    Exercisable as of June 30, 2025 
     76,579  
    $158.51  
     6.7  
    $- 
  
    Vested and expected to vest as of June 30, 2025 
     104,666  
    $125.42  
     7.3  
    $4,258 

The
following table summarizes the total stock-based compensation expense included in the unaudited condensed consolidated statements of
operations for the periods presented:

 SCHEDULE OF STOCK BASED COMPENSATION EXPENSES 

    2025  
    2024  
    2025  
    2024 

    For the three months ended  June 30,  
    For the six months ended  June 30, 

    2025  
    2024  
    2025  
    2024 
  
    Research and development 
    $59,867  
    $221,661  
    $129,529  
    $439,480 
  
    General and administrative 
     120,896  
     561,191  
     292,125  
     1,118,063 
  
    Total stock-based compensation expense 
    $180,763  
    $782,852  
    $421,654  
    $1,557,543 

As
of June 30, 2025, total compensation cost not yet recognized related to unvested stock options was approximately $0.6 million, which
is expected to be recognized over a weighted-average period of approximately 1.2 years.

The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the six months ended June 30, 2025, are presented in the table
below. The weighted average fair value of stock options granted during the six months ended June 30, 2025 was $8.14 per share.

 SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO